Ru(II) trithiacyclononane 5-(2-hydroxyphenyl)-3-[(4-methoxystyryl)pyrazole], a complex with facile synthesis and high cytotoxicity against PC-3 and MDA-MB-231 cells

J. Marques†, V.L.M. Silva†, A.M.S. Silva†, M.P.M. Marques† and S.S. Braga∗
†QOPNA, Department of Chemistry, University of Aveiro, Aveiro, Portugal; ‡“Molecular Physical-Chemistry” R&D Group, Department of Life Sciences, Faculty of Science and Technology, University of Coimbra, Coimbra, Portugal

The ruthenium(II) complex [Ru([9]aneS3)(phpz)Cl2] (1) ([9]aneS3 = trithiacyclononane, phpz = 5-(2-hydroxyphenyl)-3-[(4-methoxystyryl)pyrazole]) was readily isolated by reacting [Ru([9]aneS3)(DMSO)Cl2] with one equivalent of the ligand phpz. A combination of MS, FT–IR and solution NMR studies (1-D and 2-D) was employed to determine the structural formula of the complex 1, in which phpz coordinates in a monodentate mode to Ru(II) by a simple replacement of the leaving group DMSO of the precursor. The cytotoxic properties of 1 in vitro were investigated by determination of the half-maximal growth inhibition on the human prostate (PC-3) and breast cancer cells (MDA-MB-231).

Keywords: Ruthenium(II); Trithiacyclononane; Hydroxyphenylpyrazoles; Cytotoxicity

Cite: Complex Met. 2014, 1, 7–12
Received 19 November 2013 Accepted 7 December 2013

1. Introduction

The preparation and properties of pyrazole and its analogues are a subject of consistent interest due to their wide range of applications in various areas, namely in pharmacy [1]. Known examples of pyrazole-derived active pharmaceutical ingredients include the non-steroidal anti-inflammatory celecoxib [2,3] and sildenafil citrate for the treatment of erectile dysfunction [4]. Several pyrazole compounds also feature cytotoxic and anti-retroviral properties [5]. Crizotinib, a pyridine-pyrazole derivative, is already in use against non-small cell lung cancer [6,7], and several new pyrazole compounds developed between 2002 and 2011 showed promising antitumor activity [8]. Within these, 3(5)-(2-hydroxyphenyl)pyrazoles are of particular relevance due to their potent inhibition of the heat shock protein 90 (Hsp90) ATPase [9], a biomolecule essential for cell growth and viability which causes resistance to chemotherapy in cancer cells [10]. Copper complexes of (2-hydroxyphenyl)pyrazoles were reported to inhibit the WM-115 melanoma cancer cell line at only half of the active concentration of cisplatin [11,12].

As part of a study exploring new 3(5)-(2-hydroxyphenyl)pyrazole structures [13], this work presents the cytotoxicity against the PC-3 and MDA-MB-231 cell lines of 5-(2-hydroxyphenyl)-3-[(4-methoxystyryl)pyrazole] (phpz), both in its pure form and coordinated to ruthenium(II)-trithiacyclononane.


2. Experimental section

2.1. Materials and methods

The syntheses of phpz and [Ru([9]aneS3)(DMSO)Cl2] were previously reported [13,14]. All other chemicals were purchased from Sigma-Aldrich (Poole, UK) and used as received. Reactions were executed using standard Schlenk techniques under nitrogen atmosphere.

Microanalyses for CHNS were performed by M. Marques on a TruSpec 630-200-200 CNHS Analyzer.

Fourier-transform infrared (FT-IR) spectra were collected as KBr pellets with typically 2 mg of sample and 200 mg of KBr using a Bruker Optics Tensor 27 FT-IR spectrophotometer (4000–4000 cm⁻¹ range, 64 scans, 2 cm⁻¹ maximal resolution).

Mass spectra were performed using methanol as solvent and electrospray ionization (ESI-MS). Results were recorded in a Micromass® Q-ToF 2 mass spectrometer.

Nuclear magnetic resonance (NMR) studies in dimethyl-sulfoxide (DMSO) solution comprised 1-D (1H and 13C) or in a mixture of methanol and water (DMSO-d6: 1H 2.50 ppm and 13C 39.5 ppm). Chemical shifts are quoted in parts per million (ppm).

2.2. Preparation of [Ru([9]aneS3)(phpz)Cl2] (1)

Ru([9]aneS3)(DMSO)Cl2 (51.6 mg, 0.12 mmol) was dissolved after ca. 5 min. The solution gradually turned yellow to green and a yellow precipitate started forming after ca. 30 min. After a total of 24h reflux, the hot green solution was filtered off and the remaining product was washed with methanol (15 mL), diethyl ether (20 mL) and dried (43 mg, 54% yield).

**Anal. Caled** for (C24H28Cl2N2O2RuS3) · H2O (662.7) (%): C, 43.5; H, 4.6; N, 4.2; S, 14.5. Found: C, 43.9; H, 4.6; N, 4.3; S, 14.3.

**FT-IR** (Kbr, Tmax (cm⁻¹)): 3447 m (νO=H), 3344 m (νN=H), 1575 m (νC=N), 1515 w and 1409 w (δC···H([9]aneS3)), 497 w and 491 w (νRu–S([9]aneS3)).

**ESI+-MS** (MeOH) m/z (relative intensity %): 581 ([Ru([9]aneS3–CH2CH2)phpzCl]+, 100); 609 ([Ru([9]aneS3)phpz](Cl)+, 72).

**1H NMR** (500 MHz, DMSO-d6): δ (ppm): 12.82 (1H, s, N-H), 11.36 (1H, s, 2'-OH), 7.82 (1H, d, J = 7.7 Hz, H6'), 7.63 (1H, d, J = 16.0 Hz, Hα), 7.58 (2H, d, J = 8.3 Hz, H2',6'), 7.53 (1H, s, H4), 7.38 (1H, d, J = 16.0 Hz, Hβ), 7.27 (1H, t, J = 7.7 Hz, H4'), 7.02 (1H, d, J = 7.7 Hz, H3'), 7.00 (2H, d, J = 8.3 Hz, H3',5'), 6.98 (1H, t, J = 7.7 Hz, H5'), 3.79 (3H, s, 4''-OCH3), 3.10–2.58 and 2.41–2.31 (12H, m, CH2([-9]aneS3)).

**13C NMR** (75 MHz, DMSO-d6): δ (ppm): 159.7 (C4), 154.4 (C2',3'), 143.7 (C5), 133.5 (Cβ), 130.7 (C4'), 129.2 (C1'), 128.3 (C2',6''), 127.6 (C6'), 120.1 (C5'), 116.6 (C3',α), 114.5 (C3',5''), 113.8 (C1'), 100.9 (C4), 55.3 (4''-OCH3), 37.4, 35.1, 34.6, 34.3, 33.9, 33.2, 32.9, 32.7, 32.6, 32.4, 30.9, 30.7 (CH2([-9]aneS3)).

2.3. Cytotoxicity studies

The complex 1, phpz and cisplatin (used as positive control) were tested on the human PC-3 prostate (androgen-independent) and the MDA-MB-231 (estrogen-independent) breast cancer cell lines, using the mitochondrial dehydrogenase activity assay (MTT) for cell viability evaluation.

2.3.1. Preparation of solutions.

Stock solutions of compound 1 (4.85 mM) and the free ligand phpz (10 mM) were prepared in DMSO. Cisplatin was prepared in a concentration of 1.25 mM in phosphate buffered saline (PBS) (140.0 × 10⁻³ M NaCl, 2.7 × 10⁻³ M KCl, 1.5 × 10⁻³ M KH2PO4, 8.1 × 10⁻³ M Na2HPO4 in Milli-Q water, pH 7.4) and sterilized by filtration. Stock solutions were diluted to obtain the test solutions at the concentrations required for the biological assays. In all the experiments, for both control and treated samples, the highest concentrations of DMSO and PBS in each well were 0.5% (v/v) and 2% (v/v), respectively. MTT was prepared in PBS (5 mg mL⁻¹) and sterilized by filtration.

2.3.2. Cell culture.

The MDA-MB-231 cell line (human Caucasian estrogen-independent breast adenocarcinoma) was purchased from the European Collection of Cell Cultures (ECACC, Salisbury, UK), while the PC-3 line (human Caucasian androgen-independent prostate cancer) was kindly provided by the Faculty of Medicine’s Biochemistry Service, University of Coimbra (Portugal).

The two cell lines were grown in monolayers in 75 cm² tissue culture flasks at 37°C in a humidified atmosphere with 5% CO₂, sub-cultured every 2–3 days and harvested upon addition of trypsin/EDTA (0.05% trypsin/EDTA solution). The culture medium was RPMI 1640, supplemented with sodium bicarbonate (1.5 g L⁻¹), 10% heat-inactivated fetal bovine serum (FBS) and penicillin–streptomycin (100 units mL⁻¹ penicillin and 100 µg mL⁻¹ streptomycin) for PC-3 cells.
and with sodium bicarbonate (1.5 g L$^{-1}$), 10% heat-inactivated FBS, non-essential amino acids (1 mM), penicillin–streptomycin (100 units mL$^{-1}$ penicillin and 100 µg mL$^{-1}$ streptomycin) and sodium pyruvate (1 mM) for MDA-MB-231 cells.

2.3.3. Viability assay. Cell viability following exposure of the PC-3 and MDA-MB-231 cells to test solutions with different concentrations of \( \text{I, phpz and cisplatin} \) was assessed at 72 h of incubation. Each concentration was tested by three independent experiments with triplicates. PC-3 and MDA-MB-231 cells were plated at a density of \( 1.5 \times 10^4 \) cells cm$^{-2}$ in 48-well microplates. The test solutions were added 24 h after seeding and incubated at 37°C. After 72 h, 55 µL of MTT was added to each well, and the plates were incubated for 2 h. Then, MTT was removed and the cells washed with 200 µL of DMSO under stirring to remove the purple formazan crystals. The optical density was measured in a microplate reader, at 570 nm.

2.3.4. Statistical analysis. The statistical analysis of the results was performed by analysis of variance, using the Dunnett’s post hoc test for statistical comparison between the experimental data, \( p \)-values < 0.05 being deemed significant. The IC$_{50}$ values were determined using nonlinear regression analysis, fitting the results in sigmoidal dose–response curves (variable slope).

3. Results and discussion

The complex \([\text{Ru}([\text{9}])\text{aneS}_3](\text{phpz})\text{Cl}_2 \) (I) precipitated as a yellow microcrystalline solid (powder diffractogram available as supplementary information) from the reaction of \([\text{Ru}([\text{9}])\text{aneS}_3]((\text{DMSO})\text{Cl}_2 \) with one molar equivalent of phpz. It is partially soluble in polar solvents such as dimethylsulfoxide, methanol or water.

As will be described below, solution-phase NMR studies of the complex \( \text{I} \) revealed that the coordination of the ligand phpz occurred in a monodentate fashion at the N2 of the pyrazole moiety (Figure 1). The FT-IR spectrum of \( \text{I} \), though not showing the Ru–N vibration which lies below 400 cm$^{-1}$, is in accordance with this structure since a redshift is observed for the pyrazole’s N–H and C=N bands, associated with metal coordination \[15\]. The N–H stretch suffers a redshift and the O–H stretch, absent from the spectrum of phpz, appears as a broad band at 3447 cm$^{-1}$.

The positive ESI-MS spectrum of \( \text{I} \) (in methanol) shows the most intense peak at \( m/z = 581 \), corresponding to \([\text{Ru}([\text{9}])\text{aneS}_3-\text{CH}_2\text{CH}_2](\text{phpz})\text{Cl})^+ \), a fragment generated by the loss of one ethylene unit of trithiaacyclononane along with one chloride, while the peak of the molecular cation, \([\text{Ru}([\text{9}])\text{aneS}_3](\text{phpz})\text{Cl})^+ \) (\( m/z = 609 \)), is second in intensity.

Solution-phase NMR studies determined the structure and geometry of the coordinated phpz in complex \( \text{I} \). Free phpz, like most pyrazoles, has two tautomers (Figure 2), along with a trans-vinyllic system (Ca=Cβ). Its \( ^1\text{H} \) NMR spectrum, represented in Figure 3 (bottom), presents four deshielded broad singlets attributed to the NH and C2β–OH resonances of the two prototropic isomer forms. The hydroxyl proton usually appears at a higher frequency than the NH because it is involved in an intramolecular hydrogen bond with the N2 (OH···N tautomer, phpz-I). In a DMSO-d$_6$ solution, this OH···N2 bridge is partially replaced by another with DMSO and the resonances of the NH···O tautomer (phpz-II) can be observed, although with less intensity. Indeed, the two most intense signals (C2β–OH at 13.32 and NH at 10.91 ppm) of the spectrum of the phpz ligand are ascribed to phpz-I and the two less intense (2’–OH = 12.77 and NH = 10.25 ppm) to phpz-II.

In the \( ^1\text{H} \) NMR spectrum of the complex \( \text{I} \) (Figure 3, top), the Hβ signal of coordinated phpz is slightly shifted downfield (0.17 ppm) and the Hα affords a doublet (\( ^3J_{α,β} = 16.0 \) Hz), indicating a trans configuration for Ca=Cβ in the Ru-coordinated phpz. The NH proton appears deshielded to 12.82 ppm (shift of 2.57 ppm), which is associated with N2-coordination of phpz to the ruthenium cation (details in the next paragraph) and with the presence of an NH···O bridge with the hydroxyl (i.e. ruthenium-coordinated phpz-II). The resonances of the methoxybenzene moiety are unshifted, and the \([\text{9}])\text{aneS}_3 \) macrocycle appears as a multiplet at 3.10–2.58 ppm. A summary of the \( ^1\text{H} \) NMR spectral data for the complex \( \text{I} \) and the pure ligand is presented in Table 1.

The 2-D NMR evidences monodentate coordination of the phpz-II tautomer to Ru(II)[9]aneS$_3$ via the N2
Figure 2. Two tautomeric forms I and II of phpz with the corresponding carbon labeling.

Figure 3. $^1$H NMR spectrum in DMSO-d$_6$ solution of the free phpz ligand (bottom) and of the complex 1 (top). $x_M$ — free MeOH.

position. The resonances of the carbon atoms can be observed in the $^{13}$C NMR 1-D spectrum of 1 (Figure 4, top) and their chemical shift values are listed in Table 2. Within the methine carbons (identified by the $^1$J HSQC correlations) the highest downfield shift was observed in the C$\alpha$ (ca. 4 ppm), followed closely by the quaternary pyrazolylic carbons C3 and C5 (identified by $^2$J and $^3$J HMBC correlations) and the C$\beta$ (ca. 2–3 ppm). In turn, the phenolic C2' and C1' appear shifted upfield (ca. 1–3 ppm); these shifts, in association with the shift of the 2'-OH proton (also identified from HMBC correlations) allow us to infer that the O–H····$ds$ bridge ($ds$: deuterated solvent) in 1 is weaker than in free phpz-II. The carbons of the methoxybenzene were not affected by the coordination, similar to their corresponding proton signals. Trithiacyclononane carbons afford 12 resonances (with six sharp and six broad signals) between 37.4 and 30.7 ppm.

The cytotoxicity of phpz and 1 in comparison with cisplatin was evaluated against the PC-3 prostate and MDA-MB-231 breast cancer cell lines (Table 3). Phpz
Figure 4. $^{13}$C NMR spectrum in DMSO-d$_6$ of the phpz ligand in the tautomeric form II (bottom) and of the complex 1 (top).

Table 1. $^1$H NMR chemical shifts and proton coupling constants of the ligand phpz and the complex 1 in DMSO-d$_6$.

| Attribution       | phpz     |          | I        |          |
|-------------------|----------|----------|----------|----------|
|                   | $^1$H (ppm) | $^1$H (Hz) | $^1$H (ppm) | $^1$H (Hz) |
| $4''$-OCH$_3$     | 3.78 (s)  | –        | 3.79 (s)  | –        |
| H$_2''$, H$_6''$  | 7.52 (d)  | 8.6      | 7.58 (d)  | 8.3      |
| H$_3''$, H$_5''$  | 6.97 (d)  | 8.6      | 7.00 (d)  | 8.3      |
| 2$''$-O H (phpz-I)| 13.32 (br s) | –  | –        | –        |
| 2$''$-O H (phpz-II)| 12.77 (br s) | –  | 11.36 (s) | –        |
| H$_3'$            | 6.93 (d)  | 7.7      | 7.02 (d)  | 7.7      |
| H$_4'$            | 7.16–7.20 (m) | –  | 7.27 (t)  | 7.7      |
| H$_5'$            | 6.90 (t)  | 7.7      | 6.98 (t)  | 7.7      |
| H$_6'$            | 7.71 (br s) | –  | 7.82 (d)  | 7.7      |
| H$_4''$           | 7.02 (s)  | –        | 7.53 (s)  | –        |
| H$_6''$           | 7.00 (d)  | 17.2     | 7.63 (d)  | 16.0     |
| H$_4''$           | 7.23 (br s) | –  | 7.38 (d)  | 16.0     |
| N/H (phpz-I)      | 10.91 (br s) | –  | –        | –        |
| N/H (phpz-II)     | 10.25 (br s) | –  | 12.82 (s) | –        |
| C$_2'$-[*]aneS$_3$| –        | 3.10–2.58 (m) | –  | –        |

Note: The DMSO-d$_6$ signal (2.50 ppm) was used as the internal reference.

Table 2. $^{13}$C NMR chemical shifts of the tautomer phpz-II and the complex 1 in DMSO-d$_6$.

| Attribution       | phpz-II |          | I        |          |
|-------------------|----------|----------|----------|----------|
|                   | $^1$H (ppm) | $^1$H (Hz) | $^1$H (ppm) | $^1$H (Hz) |
| $4''$-O CH$_3$    | 55.3     | –        | 55.3     | –        |
| C$_1''$           | 128.9    | –        | 129.2    | –        |
| C$_2''$           | 127.9    | –        | 128.3    | –        |
| C$_3''$           | 114.4    | –        | 114.5    | –        |
| C$_4''$           | 159.4    | –        | 159.7    | –        |
| C$_5''$           | 114.4    | –        | 114.5    | –        |
| C$_6''$           | 127.9    | –        | 128.3    | –        |
| C$_1'$            | 117.1    | –        | 113.8    | –        |
| C$_2'$            | 155.2    | –        | 154.4    | –        |
| C$_3'$            | 116.5    | –        | 116.6    | –        |
| C$_4'$            | 128.9    | –        | 130.7    | –        |
| C$_5'$            | 119.3    | –        | 120.1    | –        |
| C$_6'$            | 126.9    | –        | 127.6    | –        |
| C$_3$             | 151.0    | –        | 154.4    | –        |
| C$_4$             | 100.1    | –        | 100.9    | –        |
| C$_5$             | 142.2    | –        | 143.7    | –        |
| C$_4$             | 113.0    | –        | 116.6    | –        |
| C$_5$             | 130.8    | –        | 133.5    | –        |
| C$_2'$-[*]aneS$_3$| –        | 37.4, 35.1, 34.6, 34.3, 33.9, 33.2, 32.9, 32.7, 32.6, 32.4, 30.9, 30.7 |

Note: The DMSO-d$_6$ signal (39.5 ppm) was used as the internal reference.
Table 3. Inhibition (IC₅₀ values) at 72 h of incubation of PC-3 and MDA-MB-231 cells by phpz and 1.

|       | PC-3 (µM) | MDA-MB-231 (µM) |
|-------|-----------|-----------------|
| phpz  | 9.9       | 10.2            |
| 1     | 32.3      | 19.2            |
| cisplatin* | 6.6    | 9.5             |

*Included as a positive control.

displayed the expected high biological activity, with IC₅₀ values comparable to those of cisplatin. Several such pyrazoles have antineoplastic action, coupled with low toxic profiles [16]. Moreover, structure–activity relationship studies on the growth inhibition of MCF-7 cells by 2-hydroxyphenylated 4,5-dihydro-2H-pyrazoles evidenced higher activity (IC₅₀ ≤ 4 µM) associated with a para electron-donating OCH₃ group [17]. Complex 1 has IC₅₀ values of 19.2 µM and 32.3 µM, respectively, against the MDA-MB-231 and PC-3 cells. While lower to phpz’s, the activity of 1 against MDA-MB-231 is nonetheless 4× superior to [Ru([9]aneS₃)(en)Cl]₂, the most active Ru(II)-trithiacyclononane reported to date [18].

4. Conclusion

The new complex herein presented, [Ru([9]aneS₃)(phpz)Cl₂] (1), combines a facile one-step synthesis with a notable cytotoxic action towards the MDA-MB-231 and PC-3 human cancer cell lines. Given its potential value, both phpz and the complex 1 warrant further studies on healthy human cells, regarding toxicological safety. Should these studies demonstrate that coordination to ruthenium plays a key role in the selectivity of action of phpz towards cancer cells, the coordination of phpz to other ruthenium scaffolds will be contemplated as a follow-up study.

Supplementary material

Powder X-ray diffraction data and tables with the full listing and description of the ¹H and ¹³C chemical shifts of the organic ligand phpz and the complex 1 are presented as electronic supplementary information.

Funding

We acknowledge Fundação para a Ciência e a Tecnologia (FCT), the European Union, QREN, FEDER, COMPETE, for funding QOPNA (Organic Chemistry Research Unit) (project Pest-C/QUI/UI0062/2013; FCOMP-01-0124-FEDER-037296). The FCT and the European Social Fund, through the Programa Operacional Potencial Humano (POPH), are acknowledged for J.M.’s Ph.D. grant (SFRH/BD/44791/2008).

Supplemental data

Supplemental data for this article can be accessed http://dx.doi.org/10.1080/2164232X.2013.873992.

References

[1] J. Elguero. In Comprehensive Heterocyclic Chemistry II, A.R. Katritzky, C.W. Rees, E.F.V. Scriven (Eds), pp. 1–75, Pergamon, Oxford (1996).
[2] T.D. Penning, J.J. Talley, S.R. Bertenshaw, J.S. Carter, P.W. Collins, S. Docter, M.J. Graneto, L.F. Lee, J.W. Malecha, J.M. Miyashiro, R.S. Rogers, D.J. Rogier, S.S. Yu, G.D. Anderson, E.G. Burton, J.N. Cogburn, S.A. Gregory, C.M. Koboldt, W.E. Perkins, K. Seibert, A.W. Veenhuizen, Y.Y. Zhang, P.C. Isakson. J. Med. Chem., 40, 1347 (1997).
[3] J.-M. Dogné, C.T. Supuran, D. Pratico. J. Med. Chem., 48, 2251 (2005).
[4] H. Padma-Nathan. Int. J. Impot. Res., 18, 423 (2006).
[5] T. Mizuhara, T. Kato, A. Hirai, H. Kurihara, Y. Shimada, M. Taniguchi, H. Maeta, H. Tomogi, K. Shimura, M. Matsuoka, S. Okazaki, T. Takeuchi, H. Ohno, S. Oishi, N. Fujii. Bioorg. Med. Chem. Lett., 23, 4557 (2013).
[6] G. Scagliotti, R.A. Stahel, R. Rosell, N. Thatcher, J.-C. Soria. Eur. J. Cancer, 48, 961 (2012).
[7] W.T. Elliott, C. James. Intern. Med. Alert, 33, 142 (2011).
[8] D. Pal, S. Saha, S. Singh. Int. J. Pharm. Pharm. Sci., 4, 98 (2012).
[9] P.A. Brough, X. Barril, M. Beswick, B.W. Dymock, M.J. Drysdale, L. Wright, K. Grant, A. Massey, A. Surgenor, P. Workman. Bioorg. Med. Chem. Lett., 15, 5197 (2005).
[10] G. Jego, A. Hazoumé, R. Seigneuric, C. Garrido. Cancer Lett., 332, 275 (2013).
[11] E. Budzisz, M. Miernicka, I.-P. Lorenz, P. Mayer, U. Krajewska, M. Rozalski. Polyhedron, 28, 637 (2009).
[12] E. Budzisz, M. Miernicka, I.-P. Lorenz, P. Mayer, E. Balcerzak, U. Krajewska, M. Rozalski. Eur. J. Med. Chem., 45, 2613 (2010).
[13] V.L.M. Silva, A.M.S. Silva, D.C.G.A. Pinto, J.A.S. Cavaleiro, J. Elguero. Eur. J. Org. Chem., 2004, 4348 (2004).
[14] C. Landgrafe, W.S. Sheldrick. J. Chem. Soc., Dalton Trans., 1885 (1994).
[15] S.M.E. Khalil. J. Coord. Chem., 56, 1013 (2003).
[16] R.M. Mohareb, A.A. Fahmy. Eur. Chem. Bull., 2, 545 (2013).
[17] J.-J. Liu, H. Zhang, J. Sun, Z.-C. Wang, Y.-S. Yang, D.-D. Li, F. Zhang, H.-B. Gong, H.-L. Zhu. Bioorg. Med. Chem., 20, 6089 (2012).
[18] I. Bratsos, E. Mitri, F. Ravalico, E. Zangrando, T. Gianferrara, A. Bergamo, E. Alessio. Dalton Trans., 41, 7358 (2012).